AGP Picks
View all

Health Times of Africa
Provided by AGP

Health Times of Africa: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Africa.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on September 29, 2026

Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors
Sep. 29, 2026

Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors

Indeterminate GlobeNewswire
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Sep. 29, 2026

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Indeterminate GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Sep. 29, 2026

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Indeterminate GlobeNewswire
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Sep. 29, 2026

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

Indeterminate GlobeNewswire
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Sep. 29, 2026

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

Indeterminate GlobeNewswire
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Sep. 29, 2026

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

Indeterminate GlobeNewswire
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for…
Sep. 29, 2026

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for…

Indeterminate GlobeNewswire
Canada’s Coffee Industry Generates $34.7 Billion in Economic Impact
Sep. 29, 2026

Canada’s Coffee Industry Generates $34.7 Billion in Economic Impact

Indeterminate GlobeNewswire
Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation
Sep. 29, 2026

Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation

Indeterminate GlobeNewswire
4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
Sep. 29, 2026

4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines

Indeterminate GlobeNewswire
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Sep. 29, 2026

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Indeterminate GlobeNewswire
ANJAC HEALTH & BEAUTY LAUNCHES A DEDICATED OFFERING TO SUPPORT PATIENTS ON GLP-1 TREATMENTS
Sep. 29, 2026

ANJAC HEALTH & BEAUTY LAUNCHES A DEDICATED OFFERING TO SUPPORT PATIENTS ON GLP-1 TREATMENTS

Indeterminate GlobeNewswire
Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
Sep. 29, 2026

Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial

Indeterminate GlobeNewswire
Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD
Sep. 29, 2026

Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD

Indeterminate GlobeNewswire
Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
Sep. 29, 2026

Breye Therapeutics raises €67.5 million in over-subscribed Series A financing

Indeterminate GlobeNewswire
Pentagon Pivots on Havana Syndrome with Re-Branding, Compensation, and a New Study
Sep. 29, 2026

Pentagon Pivots on Havana Syndrome with Re-Branding, Compensation, and a New Study

Indeterminate GlobeNewswire
Rapid Nutrition Reports Record Q3 Group Revenue Averaging $1 Million per Month, Up More Than 1,000% on FY2025 Monthly Average
Sep. 29, 2026

Rapid Nutrition Reports Record Q3 Group Revenue Averaging $1 Million per Month, Up More Than 1,000% on FY2025 Monthly Average

Indeterminate GlobeNewswire
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
Sep. 29, 2026

AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection

Indeterminate GlobeNewswire
AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques
Sep. 29, 2026

AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques

Indeterminate GlobeNewswire
Carbios and the Fiber-to-Fiber Consortium successfully validate the industrial-scale production of recycled polyester T-shirts made from complex plastic and textile waste.
Sep. 29, 2026

Carbios and the Fiber-to-Fiber Consortium successfully validate the industrial-scale production of recycled polyester T-shirts made from complex plastic and textile waste.

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Times of Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.